BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure ...

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdastifan leading the way in targeting large ...